Our emerging Differentiated Formulations portfolio consists of developing novel formulations of currently marketed drugs or combinations thereof to enhance patient comfort.
We develop synergistic combinations as well as technologies that enhance the drug’s safety and/or efficacy profile by modifying its pharmacokinetics.
Our most advanced Differentiated Formulations efforts are in dermatology, where we have launched several effective and innovative products through our wholly owned subsidiary Promius Pharma™.
Our wholly-owned subsidiary, headquartered at Bridgewater, New Jersey (US) develops and markets differentiated formulations for important dermatological indications.
Our portfolio includes in-licensed and co-developed dermatological products and an internal pipeline of topical products under development that will provide better answers to the skin care needs of today and tomorrow.
Promius Pharma has entered into successful partnerships with companies such as Ceragenix, Foamix, Sinclair and Antares for in-licensing of products.
For more information about Promius Pharma, please visit www.promiuspharma.com